Liquidia Co. (NASDAQ:LQDA - Get Free Report) General Counsel Russell Schundler sold 1,063 shares of the company's stock in a transaction dated Monday, December 2nd. The stock was sold at an average price of $11.51, for a total transaction of $12,235.13. Following the completion of the transaction, the general counsel now owns 487,328 shares of the company's stock, valued at approximately $5,609,145.28. This trade represents a 0.22 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link.
Russell Schundler also recently made the following trade(s):
- On Monday, October 14th, Russell Schundler sold 2,576 shares of Liquidia stock. The stock was sold at an average price of $11.11, for a total value of $28,619.36.
Liquidia Stock Performance
NASDAQ LQDA opened at $11.26 on Wednesday. The stock has a market capitalization of $953.05 million, a P/E ratio of -6.91 and a beta of 0.22. The business's fifty day moving average is $10.78 and its two-hundred day moving average is $11.33. Liquidia Co. has a 1 year low of $6.83 and a 1 year high of $16.99.
Institutional Investors Weigh In On Liquidia
⭕ [URGENT] Buy Alert just triggered
From Behind the Markets | Ad
My absolute favorite stock just hit a critical "buy now" trigger price.
Click here for the ticker >>>
Hedge funds have recently modified their holdings of the stock. Vanguard Group Inc. grew its position in Liquidia by 1.5% during the 1st quarter. Vanguard Group Inc. now owns 2,887,274 shares of the company's stock worth $42,587,000 after purchasing an additional 43,352 shares in the last quarter. Whitefort Capital Management LP grew its holdings in shares of Liquidia by 119.8% during the third quarter. Whitefort Capital Management LP now owns 1,702,025 shares of the company's stock valued at $17,020,000 after buying an additional 927,546 shares in the last quarter. Charles Schwab Investment Management Inc. grew its holdings in shares of Liquidia by 144.8% during the third quarter. Charles Schwab Investment Management Inc. now owns 390,257 shares of the company's stock valued at $3,903,000 after buying an additional 230,820 shares in the last quarter. Bank of New York Mellon Corp lifted its stake in Liquidia by 18.2% in the 2nd quarter. Bank of New York Mellon Corp now owns 207,961 shares of the company's stock worth $2,496,000 after acquiring an additional 32,076 shares in the last quarter. Finally, HighVista Strategies LLC boosted its position in Liquidia by 48.6% during the 3rd quarter. HighVista Strategies LLC now owns 180,947 shares of the company's stock worth $1,809,000 after acquiring an additional 59,193 shares during the period. 64.54% of the stock is owned by hedge funds and other institutional investors.
Wall Street Analysts Forecast Growth
LQDA has been the subject of a number of analyst reports. BTIG Research reduced their price target on Liquidia from $29.00 to $25.00 and set a "buy" rating for the company in a research report on Monday, August 19th. Needham & Company LLC reiterated a "buy" rating and issued a $19.00 target price on shares of Liquidia in a research report on Thursday, November 14th. Bank of America dropped their price target on shares of Liquidia from $24.00 to $23.00 and set a "buy" rating on the stock in a research report on Tuesday, August 20th. Raymond James upgraded shares of Liquidia from an "outperform" rating to a "strong-buy" rating in a report on Monday, August 19th. Finally, HC Wainwright reiterated a "buy" rating and set a $29.00 price objective on shares of Liquidia in a research note on Thursday, November 14th. One analyst has rated the stock with a sell rating, one has given a hold rating, six have assigned a buy rating and two have given a strong buy rating to the company's stock. According to MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus target price of $24.00.
Get Our Latest Stock Report on LQDA
About Liquidia
(
Get Free Report)
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
